PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF CAFFEINE - TOLERANCE TO PRESSOR EFFECTS

被引:76
|
作者
SHI, J
BENOWITZ, NL
DENARO, CP
SHEINER, LB
机构
[1] SAN FRANCISCO GEN HOSP,MED CTR,DIV CLIN PHARMACOL & EXPTL THERAPEUT,MED SERV,CLIN PHARMACOL UNIT,SAN FRANCISCO,CA 94110
[2] UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143
[3] UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143
[4] UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143
关键词
D O I
10.1038/clpt.1993.3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We propose a parametric pharmacokinetic-pharmacodynamic model for caffeine that quantifies the development of tolerance to the pressor effect of the drug and characterizes the mean behavior and inter-individual variation of both pharmacokinetics and pressor effect. Our study in a small group of subjects indicates that acute tolerance develops to the pressor effect of caffeine and that both the pressor effect and tolerance occur after some time delay relative to changes in plasma caffeine concentration. The half-life of equilibration of effect with plasma caffeine concentration is about 20 minutes. The half-life of development and regression of tolerance is estimated to be about 1 hour, and the model suggests that tolerance, at its fullest, causes more than a 90% reduction of initial (nontolerant) effect. Whereas tolerance to the pressor effect of caffeine develops in habitual coffee drinkers, the pressor response is regained after relatively brief periods of abstinence. Because of the rapid development and regression of tolerance, the pressor response to caffeine depends on how much caffeine is consumed, the schedule of consumption, and the elimination half-life of caffeine.
引用
收藏
页码:6 / 14
页数:9
相关论文
共 50 条
  • [1] POPULATION PHARMACOKINETIC MODELING PHARMACODYNAMIC MODELING OF CAFFEINE - TOLERANCE TO PRESSOR EFFECTS
    SHI, J
    BENOWITZ, NL
    DENARO, CP
    SHEINER, LB
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (02) : 161 - 161
  • [2] ACUTE TOLERANCE TO FUROSEMIDE DIURESIS IN HUMANS - PHARMACOKINETIC-PHARMACODYNAMIC MODELING
    HAMMARLUND, MM
    ODLIND, B
    PAALZOW, LK
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1985, 233 (02): : 447 - 453
  • [3] Pharmacokinetic-pharmacodynamic modeling:: Why?
    Pérez-Urizar, J
    Granados-Soto, V
    Flores-Murrieta, FJ
    Castañeda-Hernández, G
    ARCHIVES OF MEDICAL RESEARCH, 2000, 31 (06) : 539 - 545
  • [4] Pharmacokinetic-pharmacodynamic modeling of opioids
    Lötsch, JR
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2005, 29 (05) : S90 - S103
  • [5] PHARMACOKINETIC-PHARMACODYNAMIC MODELING IN PAIN
    Loetsch, J.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 14 - 14
  • [6] Pharmacokinetic-pharmacodynamic modeling of the miotic effects of dihydrocodeine in humans
    Schmidt, Helmut
    Loetsch, Joern
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (11) : 1045 - 1054
  • [7] A pharmacokinetic-pharmacodynamic model of acute tolerance to the subjective effects of alcohol
    Ramchandani, VA
    Hoefer, ME
    Edenberg, EF
    Walker, JT
    Hommer, DW
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2005, 29 (05) : 66A - 66A
  • [8] CONCEPTS AND USEFULNESS OF PHARMACOKINETIC-PHARMACODYNAMIC MODELING
    HOLFORD, NHG
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1990, 4 : S93 - S101
  • [9] APPLICATION OF PHARMACOKINETIC-PHARMACODYNAMIC MODELING TO ANALGESIA
    INTURRISI, CE
    COLBURN, WA
    ADVANCES IN PAIN RESEARCH AND THERAPY, 1986, 8 : 441 - 452
  • [10] Pharmacokinetic-Pharmacodynamic Modeling of Propofol in Children
    Rigouzzo, Agnes
    Servin, Frederique
    Constant, Isabelle
    ANESTHESIOLOGY, 2010, 113 (02) : 343 - 352